Search research articles
Contact Us
Filters
Showing results (11-20 of 22) with videos related to
Page
of 3
Sort By:
European Journal of Obstetrics, Gynecology, and Reproductive Biology
|
February 22, 2022
Surgical management and outcomes for stage 1 malignant ovarian germ cell tumours: A UK multicentre retrospective cohort study
Radha Graham, Nicola D MacDonald, Michelle Lockley, et al.
BMJ Open
|
January 14, 2025
Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancer
Uma Anne Mukherjee, Helen Hockings, Nicholas Counsell, et al.
Gynecologic Oncology
|
October 3, 2022
A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer
Panagiotis A Konstantinopoulos, Jung-Min Lee, Bo Gao, et al.
Nature Communications
|
December 14, 2016
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
Chris T Williamson, Rowan Miller, Helen N Pemberton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2023
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, et al.
British Journal of Cancer
|
April 8, 2026
Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
Yvette Drew, Lucy Gilbert, Alejandro Martinez Bueno, et al.
Cell Reports
|
March 8, 2016
Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines
James Campbell, Colm J Ryan, Rachel Brough, et al.
JAMA Network Open
|
November 2, 2023
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial
Thierry André, Dominique Berton, Giuseppe Curigliano, et al.
Nature Communications
|
July 25, 2023
Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial
James Spicer, Bristi Basu, Ana Montes, et al.
Scientific Reports
|
July 15, 2018
Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness
Harriett Holme, Aditi Gulati, Rachel Brough, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 22) with videos related to
Sort By:
Page
of 3
European Journal of Obstetrics, Gynecology, and Reproductive Biology
|
February 22, 2022
Surgical management and outcomes for stage 1 malignant ovarian germ cell tumours: A UK multicentre retrospective cohort study
Radha Graham, Nicola D MacDonald, Michelle Lockley, et al.
BMJ Open
|
January 14, 2025
Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancer
Uma Anne Mukherjee, Helen Hockings, Nicholas Counsell, et al.
Gynecologic Oncology
|
October 3, 2022
A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer
Panagiotis A Konstantinopoulos, Jung-Min Lee, Bo Gao, et al.
Nature Communications
|
December 14, 2016
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
Chris T Williamson, Rowan Miller, Helen N Pemberton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2023
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, et al.
British Journal of Cancer
|
April 8, 2026
Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
Yvette Drew, Lucy Gilbert, Alejandro Martinez Bueno, et al.
Cell Reports
|
March 8, 2016
Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines
James Campbell, Colm J Ryan, Rachel Brough, et al.
JAMA Network Open
|
November 2, 2023
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial
Thierry André, Dominique Berton, Giuseppe Curigliano, et al.
Nature Communications
|
July 25, 2023
Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial
James Spicer, Bristi Basu, Ana Montes, et al.
Scientific Reports
|
July 15, 2018
Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness
Harriett Holme, Aditi Gulati, Rachel Brough, et al.
Page
of 3